Tumor immunotherapy, which is used to treat cancers in this era of precision medicine, works by resuming and maintaining the tumor-immune cycle and restoring the body's normal anti-tumor immune response. Tumor immunotherapy has been proven with efficacy in different tumors. However, there are still quite a lot of patients suffering from severe side effects and ineffective treatment outcomes. Even some candidate biomarkers, including PD-L1, still have a limited scope of application. In order to increase the efficacy of immunotherapy, it is critical to find new immunotherapy biomarkers and investigate prospective targets.
Since apoptosis resistance is a common feature of malignancies, inducing non-apoptotic regulated cell death is developing as a potential cancer therapeutic method. Recent research has clarified how non-apoptotic regulated cell death and antitumor immunity interact. In particular, non-apoptotic controlled cell death, such as autophagy, ferroptosis, pyroptosis, and so forth, synergistically induces anticancer immune responses while simultaneously possibly inhibiting them. As a result, immunotherapy in combination with targeted therapies (inducers or inhibitors) against non-apoptotic regulated cell death may have decisive anticancer action, even in cancers resistant to immunotherapy. Thus, by exploring the multilevel relationship between antitumor immunity and non-apoptotic regulated cell death, the potential targeting application of non-apoptotic regulated cell death to improve the efficacy of immunotherapy in malignancy is significant.
Besides, multiple studies have demonstrated the efficacy of combining immunotherapy and chemotherapy. Thus, exploring biomarkers and therapeutic targets for combining immunotherapy and chemotherapy is also significant.
1. Using novel methods or technologies to identify non-apoptotic regulated cell death-related biomarkers for cancer immunotherapy.
2. The molecular mechanisms between antitumor immunity and non-apoptotic regulated cell death.
3. Potential therapeutic targets of non-apoptotic regulated cell death to improve the efficacy of immunotherapy in malignancy.
4. Strategies for chemotherapy and immunotherapy in combination.
Please Note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Tumor immunotherapy, which is used to treat cancers in this era of precision medicine, works by resuming and maintaining the tumor-immune cycle and restoring the body's normal anti-tumor immune response. Tumor immunotherapy has been proven with efficacy in different tumors. However, there are still quite a lot of patients suffering from severe side effects and ineffective treatment outcomes. Even some candidate biomarkers, including PD-L1, still have a limited scope of application. In order to increase the efficacy of immunotherapy, it is critical to find new immunotherapy biomarkers and investigate prospective targets.
Since apoptosis resistance is a common feature of malignancies, inducing non-apoptotic regulated cell death is developing as a potential cancer therapeutic method. Recent research has clarified how non-apoptotic regulated cell death and antitumor immunity interact. In particular, non-apoptotic controlled cell death, such as autophagy, ferroptosis, pyroptosis, and so forth, synergistically induces anticancer immune responses while simultaneously possibly inhibiting them. As a result, immunotherapy in combination with targeted therapies (inducers or inhibitors) against non-apoptotic regulated cell death may have decisive anticancer action, even in cancers resistant to immunotherapy. Thus, by exploring the multilevel relationship between antitumor immunity and non-apoptotic regulated cell death, the potential targeting application of non-apoptotic regulated cell death to improve the efficacy of immunotherapy in malignancy is significant.
Besides, multiple studies have demonstrated the efficacy of combining immunotherapy and chemotherapy. Thus, exploring biomarkers and therapeutic targets for combining immunotherapy and chemotherapy is also significant.
1. Using novel methods or technologies to identify non-apoptotic regulated cell death-related biomarkers for cancer immunotherapy.
2. The molecular mechanisms between antitumor immunity and non-apoptotic regulated cell death.
3. Potential therapeutic targets of non-apoptotic regulated cell death to improve the efficacy of immunotherapy in malignancy.
4. Strategies for chemotherapy and immunotherapy in combination.
Please Note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
